🔗 Share this article

Government ministers and leading parliamentarians have expressed alarm that the United Kingdom's series of deals with Washington are "fundamentally unstable." This follows revelations that a much-touted deal on drug pricing, which pledges zero tariffs in exchange for the NHS facing higher prices, lacks any formal legal text beyond broad headline terms outlined by government press releases.

Lacking Legal Footing

The arrangement concerning medicines, promoted as a "significant" achievement, remains an "statement of intent" without formal ratification. Critics have noted that the public statements from the UK and US governments frame the deal in sharply different terms. The British version focuses on securing "duty-free access" as a unique achievement, while the American announcement highlights the expectation for the NHS to pay higher prices for new medications.

"The danger exists that the UK government has made commitments to increase medicine costs in return for nothing more than a assurance from President Trump," said David Henig, a trade policy analyst. "We know he has form for not following through on agreements."

A Pattern of Unreliability

Anxieties have been amplified by Washington's recent decision to pause the major technology agreement, which was previously called "a transformative pact" in the bilateral relationship. The US cited a failure to advance from the UK on lowering trade barriers as the reason for the pause.

Furthermore, concessions agreed to for British farmers as part of an earlier tariff deal have still not been formally ratified by the US, despite a imminent January deadline. "We have been informed that that the US has not yet signed off the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

Privately, ministers have expressed concerns that the government's deals with Washington are flimsy and unreliable. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another described the situation as the "new normal" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, chair of the health select committee, stated: "The only thing more surprising than Trump's temper tantrums is the UK government's naive belief that his administration is a good faith actor. The NHS is not a bargaining chip."

A Mixed Picture of Success and Setback

Ministry sources have attempted to minimize the possibility of the US backing out of the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been advocating for the agreement, desiring stability on imports and pricing, making it of tangible value than the paused tech deal.

Officials acknowledge that volatility is part and parcel of dealing with the current US leadership. However, they argue that the UK has secured concrete outcomes for businesses, such as reduced duties on automobiles compared to other nations. "The fact we have 25% steel tariffs, which is better than the rate for the rest of the world, is not flimsy," one official said.

Yet, delays have arisen in carrying out the broader trade deal. Promised reciprocal agricultural allowances have not materialized, and the pledge to "eliminate duties on UK metals" has not been fulfilled, with tariffs fixed at 25%.

As negotiations continue, the two sides have scheduled to restart talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.